Ratio and Novartis Partner for Cancer Treatment
Ratio Therapeutics partners with Novartis to develop next-gen SSTR2-targeting radiopharmaceutical.
Ratio Therapeutics has entered a major collaboration with Novartis Pharma AG to develop a next-generation Somatostatin Receptor 2 (SSTR2)-targeting radiopharmaceutical for cancer treatment. Under the agreement, Ratio will receive upfront and milestone payments potentially reaching $745 million, along with tiered royalties. The companies will work together on preclinical research, with Novartis assuming responsibility for further development, manufacturing, and commercialization efforts.
This collaboration combines Ratio's expertise in radioligand therapy discovery with Novartis' capabilities in advancing cancer treatments, aiming to deliver a potent new therapeutic option for patients with SSTR2-expressing tumors.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Medicus Pharma soumet à la FDA le protocole de Phase 2b/3 pour Teverelix
Fresenius Kabi reçoit une lettre d’avertissement de la FDA après des défaillances d’enquête sur le traitement aseptique dans l’établissement de Melrose Park
Discussion